+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Myocardial Infarction Treatment Market Research and Forecast, 2018-2023

  • ID: 4751469
  • Report
  • Region: Global
  • Orion Market Research Private Limited
1 of 4

FEATURED COMPANIES

  • advanceCOR GmbH
  • Bayer AG
  • CSL Behring
  • Merck KGaA
  • Novartis AG
  • PledPharma AB
  • MORE
The myocardial infarction or heart attack is a life-threatening condition that occurs due to the blockage of one or more coronary arteries and the blockage in the blood flow to the heart muscle. There are various death cases recorded due to severe heart stroke or heart attacks. The myocardial infarction is of three type which are STEMI heart attacks, NSTEMI heart attacks, and silent heart attacks. Such diseases can be diagnosed by electrocardiography, chest x-ray, CT scan, echocardiography, blood test, and another diagnostic test. Moreover, the heart attack can be treated by several medications such as aspirin thrombolytic, antiplatelet agents, and others medicines and some surgical procedures such as angioplasty bypass surgery, heart transplant, and so on. Some of the devices used for the treatment of myocardial infarction includes left ventricular assist devices, pacemaker, and implantable cardioverter defibrillator.

Factors contributing to the growth of the myocardial infarction market includes rising incidence rate of CVDs (cardiovascular diseases) and intake of high-level sugary food, which significantly boost the prevalence of CADs (coronary artery diseases). Moreover, the shift towards sedentary lifestyle and faulty dietary habits coupled with lack of physical activities are some other factors that fuel the growth of the market. The high cost of myocardial infarction treatment and delay in certification for heart treatment are some factors restraining the growth of the market. However, the supportive laws and schemes for the reduction and prevention of heart diseases and the rising adoption of minimally invasive treatment are anticipated to create the future opportunity for the growth of the myocardial infarction market.

Geographically market is divided into North America, Europe, Asia-Pacific, and Rest of the World. North America holds a dominant position in the global myocardial infarction treatment market due to the increasing demand for emerging technologies and the affordability of such treatment in the US. However, Europe is the second largest market for myocardial infarction treatment across the globe, owing to favorable reimbursement policies and supportive laws and schemes for healthcare technology are some of the major factors fuelling the growth of the market in the region. The lack of physical activities and improvement in healthcare infrastructure which are leading to higher cholesterol and risk of stroke are some factors anticipated to drive the growth of myocardial infarction treatment market in Asia-Pacific.

Major players contributing into the growth of the global myocardial infarction treatment market includes AstraZeneca PLC, BioVascular, Inc., Merck KGaA, Johnson & Johnson Services, Inc., Pfizer Inc., Novartis AG, GlaxoSmithKline PLC, Portola Pharmaceuticals, Inc., and Teva Pharmaceuticals Industries Ltd, among others. The companies are working on developing innovative myocardial infarction treatment system through research and innovation, expansion, merger& acquisition, finding a new market or innovate in their core competency in order to expand individual market share.

Research Methodology

The market study of myocardial infarction treatment market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include
  • Financial reports of companies involved in the market
  • Authentic Public Databases such as the OECD, WHO, and others
  • Whitepapers, research-papers and news blogs
  • Company websites and their product catalog.
The report is intended for the healthcare service provider, drug manufacturer, investment companies, government organizations for overall market analysis and competitive analysis. The report provides in-depth analysis of pricing, market size and will serve as a source for 360-degree analysis of the market.

Market Segmentation

1. Global Myocardial Infarction Treatment Market Research and Analysis by Type
2. Global Myocardial Infarction Treatment Market Research and Analysis by Device
3. Global Myocardial Infarction Treatment Market Research and Analysis by Diagnosis
4. Global Myocardial Infarction Treatment Market Research and Analysis by Treatment
5. Global Myocardial Infarction Treatment Market Research and Analysis by End-Users

The Report Covers
  • Comprehensive research methodology of global myocardial infarction treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global myocardial infarction treatment market.
  • Insights about market determinants which are stimulating the global myocardial infarction treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • advanceCOR GmbH
  • Bayer AG
  • CSL Behring
  • Merck KGaA
  • Novartis AG
  • PledPharma AB
  • MORE
1. REPORT SUMMARY
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
1.2.4. Exceptions

2. MARKET OVERVIEW AND INSIGHTS
2.1. Definition
2.2. Analyst Insights & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendation
2.2.3. Conclusion
2.3. Rules & Regulation

3. MARKET DETERMINANT
3.1. Motivators
3.1.1. Rising Incidence rate of CVDs (Cardiovascular Diseases)
3.1.2. High Blood Sugar Level Leading to CADs (Coronary Artery Diseases)
3.1.3. Sedentary Lifestyle and Faulty Dietary Habits
3.1.4. Growing Healthcare Spending and Improving Healthcare System
3.2. RESTRAINTS
3.2.1. Availability of Alternate Therapies
3.2.2. High Cost of Certification and Approval for Heart Treatment
3.3. Opportunities
3.3.1. Supportive Laws and Policies for Reduction and Prevention of Heart Diseases
3.3.2. Increasing Demand for Minimally Invasive Surgery

4. MARKET SEGMENTATION
4.1. Global Myocardial Infarction Treatment Market by Type
4.1.1. ST segment elevation myocardial infarction (STEMI) Heart Attacks
4.1.2. Non-ST segment elevation myocardial infarction (NSTEMI) Heart Attacks
4.1.3. Silent Heart Attacks
4.2. Global Myocardial Infarction Treatment Market by Device
4.2.1. Left Ventricular Assist Device
4.2.2. Pacemaker
4.2.3. Implantable Cardioverter Defibrillator
4.2.4. Others (Aspiration-Based Catheters)
4.3. Global Myocardial Infarction Treatment Market by Diagnosis
4.3.1. Electrocardiography (ECG)
4.3.2. Chest X-Ray
4.3.3. Computed Tomography (CT Scan)
4.3.4. Echocardiography
4.3.5. Others (Blood Test)
4.4. Global Myocardial Infarction Treatment Market by Treatment
4.4.1. Medication
4.4.1.1. Analgesics
4.4.1.2. Thrombolytic
4.4.1.3. Antiplatelet Agents
4.4.1.4. Glycoprotein IIb/IIIa Inhibitors
4.4.1.5. Others (Adrenergic Blockers)
4.4.2. Surgery
4.4.2.1. Angioplasty
4.4.2.2. Bypass Surgery
4.4.2.3. Heart Transplant
4.5. Global Myocardial Infarction Treatment Market by End-Users
4.5.1. Hospital & Clinics
4.5.2. Ambulatory Surgical Centers
4.5.3. Research Institutes

5. COMPETITIVE LANDSCAPE
5.1. Key Strategy Analysis
5.2. Key Company Analysis

6. REGIONAL ANALYSIS
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Spain
6.2.4. France
6.2.5. Italy
6.2.6. RoE
6.3. Asia-Pacific
6.3.1. India
6.3.2. China
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World (RoW)

7. COMPANY PROFILES
7.1. advanceCOR GmbH
7.2. Anthera Pharmaceuticals, Inc.
7.3. AstraZeneca PLC
7.4. Athersys, Inc.
7.5. Bayer AG
7.6. BioVascular, Inc.
7.7. Boehringer Ingelheim International GmbH
7.8. BRISTOL-MYERS SQUIBB CO.
7.9. Caladrius Biosciences, Inc.
7.10. Capricor Therapeutics, Inc.
7.11. CSL Behring
7.12. GlaxoSmithKline PLC
7.13. GNT Pharma Co., Ltd
7.14. Johnson & Johnson Services, Inc.
7.15. Merck KGaA
7.16. Mesoblast Ltd
7.17. Mylan N.V.
7.18. NeuroVive Pharmaceutical AB
7.19. Novartis AG
7.20. Osiris Therapeutics, Inc.
7.21. Pfizer Inc.
7.22. PledPharma AB
7.23. Portola Pharmaceuticals, Inc.
7.24. Sandoz International GmbH
7.25. Sanofi SA
7.26. Teva Pharmaceutical Industries Ltd.
7.27. Ventrix, Inc.
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • advanceCOR GmbH
  • Anthera Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Athersys, Inc.
  • Bayer AG
  • BioVascular, Inc.
  • Boehringer Ingelheim International GmbH
  • BRISTOL-MYERS SQUIBB CO.
  • Caladrius Biosciences, Inc.
  • Capricor Therapeutics, Inc.
  • CSL Behring
  • GlaxoSmithKline PLC
  • GNT Pharma Co., Ltd
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Mesoblast Ltd
  • Mylan N.V.
  • NeuroVive Pharmaceutical AB
  • Novartis AG
  • Osiris Therapeutics, Inc.
  • Pfizer Inc.
  • PledPharma AB
  • Portola Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Ventrix, Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4751469
Adroll
adroll